Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aurinia Pharm Ord
(NQ:
AUPH
)
5.680
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aurinia Pharm Ord
< Previous
1
2
3
4
5
6
Next >
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Aurinia Pharmaceuticals Inc. (AUPH)
April 19, 2022
From
Robbins LLP
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Aurinia Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AUPH
April 18, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
AURINIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
April 15, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Investor Notice: Investigation over Possible Violations of Securities Laws
April 15, 2022
San Diego, CA -- (SBWIRE) -- 04/15/2022 -- An investigation was announced over potential securities laws violations by Aurinia Pharmaceuticals Inc. in connection with certain financial statements.
Via
SBWire
AUPH INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation – AUPH
April 05, 2022
From
Rosen Law Firm
Via
Business Wire
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
April 04, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
March 16, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
March 15, 2022
From
The Schall Law Firm
Via
Business Wire
AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation AUPH
March 11, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
February 28, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021
February 09, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference
February 03, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
January 04, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
December 09, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
November 10, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
November 03, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
November 01, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
October 27, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
October 26, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
September 15, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals finalizes acquisition agreement with Leading Pharma Giant
August 26, 2021
Via
Get News
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
August 17, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference
August 09, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Reports Second Quarter and Six Months 2021 Financial Results and Recent Operational Highlights
August 05, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021
July 26, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange
July 16, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs
June 30, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
June 25, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
June 14, 2021
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.